{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:19:46Z","timestamp":1790947186201,"version":"4.1.0"},"reference-count":142,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity, partly due to alterations in lipoprotein quantity, quality and cell cholesterol trafficking. Although cardiovascular disease significantly contributes to mortality excess in RA, cardiovascular prevention has been largely insufficient. Because of limited evidence, optimal strategies for lipid management (LM) in RA have not been determined yet, and recommendations are largely based on expert opinions. In this position paper, we describe abnormalities in lipid metabolism and introduce a new algorithm for estimation of cardiovascular risk (CVR) and LM in RA. The algorithm stratifies patients according to RA-related factors impacting CVR (such as RA activity and severity and medication). We propose strategies for monitoring of lipid parameters and treatment of dyslipidaemia in RA (including lifestyle, statins and other lipid-modifying therapies, and disease modifying antirheumatic drugs). These opinion-based recommendations are meant to facilitate LM in RA until more evidence is available.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvz033","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T07:34:56Z","timestamp":1565249696000},"page":"104-114","source":"Crossref","is-referenced-by-count":37,"title":["Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6939-7534","authenticated-orcid":false,"given":"Ivana","family":"Hollan","sequence":"first","affiliation":[{"name":"Lillehammer Hospital for Rheumatic Diseases , M. Grundtvigs veg 6, 2609 Lillehammer,","place":["Norway"]},{"name":"Department of Medicine, Division of Cardiovascular Medicine , 75 Francis Street, Boston, MA, 02115,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Ronda","sequence":"additional","affiliation":[{"name":"Parco Area delle Scienze 27\/A , 43124 Parma,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dessein","sequence":"additional","affiliation":[{"name":"Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand , 7 York Road, Parktown, Johannesburg 2193,","place":["South Africa"]},{"name":"Department of Rheumatology , Charlotte Maxeke Johannesburg Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Jubilee Road, Parktown, Johannesburg 2196,","place":["South Africa"]},{"name":"Rheumatology Unit, Free University Hospital, Faculty of Medicine and Pharmacy, Free University , Laarbeeklaan 103, Jette, Brussels 1090,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ullev\u00e5l , Kirkeveien 166, 0450 Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Karpouzas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Los Angeles Biomedical Research Institute , Harbor-UCLA Medical Center, 1124 W Carson Street, Building E4-R17A,Torrance, CA 90502,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tamargo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense , CIBERCV, Plaza de Ram\u00f3n y Cajal s\/n, 28040, Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Niessner","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna , Waehringer Guertel 18-20, 1090 Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Norrbacka, S1:02, Karolinska University Hospital , 171 76 Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences , IRCCS San Raffaele Roma, Via della Pisana 249, 00163 Roma,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Kaski","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Sciences Research Institute , St. George's, University of London, Cranmer Terrace, London SW17 ORE,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Wassmann","sequence":"additional","affiliation":[{"name":"Cardiology Pasing, Institutstr . 14, 81241 Munich,","place":["Germany"]},{"name":"Department of Cardiology, University of the Saarland , Kirrbergerstr. 100, 66421 Homburg\/Saar,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Meroni","sequence":"additional","affiliation":[{"name":"Immunorheumatology Research Laboratory, Istituto Auxologico Italiano , Via Ariosto, 14, 20145 Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,9]]},"reference":[{"key":"2026091105164246800_pvz033-B1","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avina-Zubieta","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2026091105164246800_pvz033-B2","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B3","doi-asserted-by":"crossref","first-page":"k1036","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications","volume":"361","author":"England","year":"2018","journal-title":"BMJ"},{"key":"2026091105164246800_pvz033-B4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.rdc.2018.03.006","article-title":"Update on cardiovascular disease risk in patients with rheumatic diseases","volume":"44","author":"Mackey","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"key":"2026091105164246800_pvz033-B5","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.berh.2016.10.001","article-title":"Metabolic abnormalities in patients with inflammatory rheumatic diseases","volume":"30","author":"Dessein","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2026091105164246800_pvz033-B6","doi-asserted-by":"crossref","first-page":"e0157360.","DOI":"10.1371\/journal.pone.0157360","article-title":"Rheumatoid arthritis disadvantages younger patients for cardiovascular diseases: a meta-analysis","volume":"11","author":"Fransen","year":"2016","journal-title":"PLoS One"},{"key":"2026091105164246800_pvz033-B7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrrheum.2015.112","article-title":"Cardiovascular comorbidity in rheumatic diseases","volume":"11","author":"Nurmohamed","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2026091105164246800_pvz033-B8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2017-211735","article-title":"Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis","volume":"77","author":"Crowson","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12026-013-8398-7","article-title":"Novel risk factors for cardiovascular disease in rheumatoid arthritis","volume":"56","author":"Amaya-Amaya","year":"2013","journal-title":"Immunol Res"},{"key":"2026091105164246800_pvz033-B10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/ard.2010.142133","article-title":"Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives","volume":"70","author":"Kitas","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B11","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/annrheumdis-2014-206411","article-title":"The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease","volume":"75","author":"Myasoedova","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/art.24390","article-title":"Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis","volume":"61","author":"Lopez-Longo","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026091105164246800_pvz033-B13","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/art.21204","article-title":"Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort","volume":"52","author":"Goodson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2026091105164246800_pvz033-B14","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B15","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/annrheumdis-2013-204715","article-title":"The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis","volume":"73","author":"Zhang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B16","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1136\/ard.2009.122226","article-title":"Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity","volume":"69","author":"Solomon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B18","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/annrheumdis-2016-211066","article-title":"Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks","volume":"76","author":"Holmqvist","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B19","doi-asserted-by":"crossref","first-page":"R131.","DOI":"10.1186\/ar3442","article-title":"Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study","volume":"13","author":"Innala","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2026091105164246800_pvz033-B20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/ard.2006.056390","article-title":"Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register","volume":"66","author":"Farragher","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2013-204531","article-title":"The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients","volume":"74","author":"Arts","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B22","doi-asserted-by":"crossref","first-page":"952.","DOI":"10.1016\/j.autrev.2015.06.004","article-title":"Prevention of cardiovascular disease in rheumatoid arthritis","volume":"14","author":"Hollan","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2026091105164246800_pvz033-B23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"Del","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026091105164246800_pvz033-B25","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/rheumatology\/kew497","article-title":"Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project","volume":"56","author":"van den Oever","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026091105164246800_pvz033-B26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/ard.2009.115717","article-title":"Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?","volume":"69","author":"Toms","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B27","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2011-200806","article-title":"Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study","volume":"71","author":"Lindhardsen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijcard.2018.06.111","article-title":"Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases","volume":"274","author":"Ikdahl","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026091105164246800_pvz033-B29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/art.20853","article-title":"Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study","volume":"52","author":"Maradit-Kremers","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2026091105164246800_pvz033-B30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/rheumatology\/keg175","article-title":"Tackling ischaemic heart disease in rheumatoid arthritis","volume":"42","author":"Kitas","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"2026091105164246800_pvz033-B31","doi-asserted-by":"crossref","first-page":"55.","DOI":"10.1186\/s13075-015-0576-7","article-title":"Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study","volume":"17","author":"Corrales","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2026091105164246800_pvz033-B32","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/annrheumdis-2012-203101","article-title":"Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study","volume":"73","author":"Corrales","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B33","doi-asserted-by":"crossref","first-page":"np1","DOI":"10.1177\/2047487316653709","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"23","author":"Piepoli","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2026091105164246800_pvz033-B34","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","author":"Grundy","year":"2018","journal-title":"Circulation"},{"key":"2026091105164246800_pvz033-B35","doi-asserted-by":"crossref","first-page":"e0174656.","DOI":"10.1371\/journal.pone.0174656","article-title":"A Trans-Atlantic Cardiovascular Risk Consortium for Rheumatoid Arthritis (ATACC-RA). Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis","volume":"12","author":"Crowson","year":"2017","journal-title":"PLoS One"},{"key":"2026091105164246800_pvz033-B36","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/annrheumdis-2013-204024","article-title":"Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis","volume":"74","author":"Arts","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B37","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/annrheumdis-2014-206879","article-title":"Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms","volume":"75","author":"Arts","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.amjcard.2012.03.044","article-title":"Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis","volume":"110","author":"Crowson","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026091105164246800_pvz033-B39","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/kex038","article-title":"Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries","volume":"56","author":"Crowson","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026091105164246800_pvz033-B40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/BOR.0000000000000378","article-title":"Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk","volume":"29","author":"Myasoedova","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"2026091105164246800_pvz033-B41","doi-asserted-by":"crossref","first-page":"497.","DOI":"10.1007\/s11882-014-0497-6","article-title":"Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship?","volume":"15","author":"Bag-Ozbek","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"2026091105164246800_pvz033-B42","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.39165","article-title":"Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients","volume":"67","author":"Liao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026091105164246800_pvz033-B43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/157016110791112269","article-title":"Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors","volume":"8","author":"Toms","year":"2010","journal-title":"Curr Vasc Pharmacol"},{"key":"2026091105164246800_pvz033-B44","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s10067-015-3049-0","article-title":"Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment","volume":"34","author":"Akiyama","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2026091105164246800_pvz033-B45","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.38920","article-title":"An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy","volume":"67","author":"Rao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026091105164246800_pvz033-B46","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00281-017-0632-2","article-title":"Cardiovascular risk in patients with rheumatoid arthritis","volume":"39","author":"Lauper","year":"2017","journal-title":"Semin Immunopathol"},{"key":"2026091105164246800_pvz033-B47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","article-title":"Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm","volume":"9","author":"Robertson","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"2026091105164246800_pvz033-B48","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.38974","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib","volume":"67","author":"Charles-Schoeman","year":"2015","journal-title":"Arthritis Rheumatology"},{"key":"2026091105164246800_pvz033-B49","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/ard.2008.101964","article-title":"Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions","volume":"68","author":"Choy","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B50","doi-asserted-by":"crossref","first-page":"8.","DOI":"10.1007\/s11926-018-0715-7","article-title":"Lipids in RA: is less not necessarily more? Lipids in RA: is less not necessarily more?","volume":"20","author":"Plutzky","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2026091105164246800_pvz033-B51","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/annrheumdis-2012-202914","article-title":"Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus","volume":"73","author":"Ronda","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B52","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2011-200493","article-title":"Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis","volume":"71","author":"Charles-Schoeman","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B53","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jacl.2017.05.009","article-title":"High triglycerides and low high-density lipoprotein cholesterol lipid profile in rheumatoid arthritis: a potential link among inflammation, oxidative status, and dysfunctional high-density lipoprotein","volume":"11","author":"Rodr\u00edguez-Carrio","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2026091105164246800_pvz033-B54","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10067-016-3456-x","article-title":"Hormone, metabolic peptide, and nutrient levels in the earliest phases of rheumatoid arthritis-contribution of free fatty acids to an increased cardiovascular risk during very early disease","volume":"36","author":"Tang","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2026091105164246800_pvz033-B55","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00296-004-0438-0","article-title":"Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation","volume":"25","author":"Dursunoglu","year":"2005","journal-title":"Rheumatol Int"},{"key":"2026091105164246800_pvz033-B56","doi-asserted-by":"crossref","first-page":"e8180.","DOI":"10.1097\/MD.0000000000008180","article-title":"Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: results from a cross-sectional, multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study","volume":"96","author":"Ruscitti","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2026091105164246800_pvz033-B57","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/03009742.2012.654815","article-title":"Apolipoprotein-defined lipoprotein abnormalities in rheumatoid arthritis patients and their potential impact on cardiovascular disease","volume":"41","author":"Knowlton","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"2026091105164246800_pvz033-B58","first-page":"53","article-title":"Metabolic cardiovascular risk burden and atherosclerosis in African black and Caucasian women with rheumatoid arthritis: a cross-sectional study","volume":"31","author":"Dessein","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2026091105164246800_pvz033-B59","first-page":"2425","article-title":"Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis","volume":"33","author":"Dessein","year":"2006","journal-title":"J Rheumatol"},{"key":"2026091105164246800_pvz033-B60","doi-asserted-by":"crossref","first-page":"e12873.","DOI":"10.1111\/eci.12873","article-title":"Evidence for increased chylomicron remnants in rheumatoid arthritis","volume":"48","author":"Burggraaf","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"2026091105164246800_pvz033-B61","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jjcc.2015.12.001","article-title":"Postprandial hyperlipidemia as a potential residual risk factor","volume":"67","author":"Nakamura","year":"2016","journal-title":"J Cardiol"},{"key":"2026091105164246800_pvz033-B62","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.108.777334","article-title":"Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events","volume":"118","author":"Mora","year":"2008","journal-title":"Circulation"},{"key":"2026091105164246800_pvz033-B63","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jbspin.2010.07.016","article-title":"Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis","volume":"78","author":"Boyer","year":"2011","journal-title":"Joint Bone Spine"},{"key":"2026091105164246800_pvz033-B64","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.4103\/0975-7406.155767","article-title":"A comparative study on serum lipoprotein (a) and lipid profile between rheumatoid arthritis patients and normal subjects","volume":"7","author":"Govindan","year":"2015","journal-title":"J Pharm Bioallied Sci"},{"key":"2026091105164246800_pvz033-B65","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026091105164246800_pvz033-B66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.17219\/acem\/29847","article-title":"Disease activity, oxidized-LDL fraction and anti-oxidized LDL antibodies influence cardiovascular risk in rheumatoid arthritis","volume":"25","author":"Nowak","year":"2016","journal-title":"Adv Clin Exp Med"},{"key":"2026091105164246800_pvz033-B67","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/rheumatology\/41.9.988","article-title":"Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis","volume":"41","author":"Cvetkovic","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"2026091105164246800_pvz033-B68","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/03009740410010308","article-title":"Which factors are related to the presence of atherosclerosis in rheumatoid arthritis?","volume":"33","author":"W\u00e5llberg-Jonsson","year":"2004","journal-title":"Scand J Rheumatol"},{"key":"2026091105164246800_pvz033-B69","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10067-017-3896-y","article-title":"High levels of oxidized fatty acids in HDL are associated with impaired HDL function in patients with active rheumatoid arthritis","volume":"37","author":"Charles-Schoeman","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2026091105164246800_pvz033-B70","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/art.38894","article-title":"Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis","volume":"67","author":"Souto","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026091105164246800_pvz033-B71","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2026091105164246800_pvz033-B72","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.38920","article-title":"An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy","volume":"67","author":"Rao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026091105164246800_pvz033-B73","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/bph.13932","article-title":"Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis","volume":"174","author":"P\u00e9rez Baos","year":"2017","journal-title":"Br J Pharmacol"},{"key":"2026091105164246800_pvz033-B74","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/art.39039","article-title":"Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism","volume":"67","author":"Ronda","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026091105164246800_pvz033-B75","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/a-0833-4627","article-title":"Effect of IL-6 receptor blockade on proprotein convertase subtilisin\/kexin type-9 and cholesterol efflux capacity in rheumatoid arthritis patients","volume":"51","author":"Ferraz-Amaro","year":"2019","journal-title":"Horm Metab Res"},{"key":"2026091105164246800_pvz033-B76","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1136\/annrheumdis-2015-207870","article-title":"Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis","volume":"75","author":"Zhang","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B77","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00296-017-3844-9","article-title":"Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study","volume":"37","author":"Kume","year":"2017","journal-title":"Rheumatol Int"},{"key":"2026091105164246800_pvz033-B78","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B79","doi-asserted-by":"crossref","first-page":"R12.","DOI":"10.1186\/ar597","article-title":"Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study","volume":"4","author":"Dessein","year":"2002","journal-title":"Arthritis Res"},{"key":"2026091105164246800_pvz033-B80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40744-016-0049-8","article-title":"Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis: a post hoc analysis","volume":"4","author":"Soubrier","year":"2017","journal-title":"Rheumatol Ther"},{"key":"2026091105164246800_pvz033-B81","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2016-209954","article-title":"Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis","volume":"76","author":"Ozen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B82","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","article-title":"Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"77","author":"Rempenault","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B83","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1136\/annrheumdis-2013-204806","article-title":"Hydrocortisone directly promotes cholesterol accumulation in macrophages","volume":"73","author":"Greco","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B84","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","article-title":"Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease","volume":"141","author":"Wei","year":"2004","journal-title":"Ann Intern Med"},{"key":"2026091105164246800_pvz033-B85","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1136\/annrheumdis-2016-210135","article-title":"Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort","volume":"76","author":"Roubille","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B86","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/rheumatology\/ker191","article-title":"Cardiovascular education for people with rheumatoid arthritis: what can existing patient education programmes teach us?","volume":"50","author":"John","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2026091105164246800_pvz033-B87","year":"2019"},{"key":"2026091105164246800_pvz033-B88","doi-asserted-by":"crossref","first-page":"R141.","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2026091105164246800_pvz033-B89","doi-asserted-by":"crossref","first-page":"1012.","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"2026091105164246800_pvz033-B90","first-page":"1263","article-title":"2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"2026091105164246800_pvz033-B91","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"ESC Scientific Document Group. 2016 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026091105164246800_pvz033-B92","doi-asserted-by":"crossref","first-page":"e6242","DOI":"10.1371\/journal.pone.0006242","article-title":"Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis","volume":"4","author":"Graf","year":"2009","journal-title":"PLoS One"},{"key":"2026091105164246800_pvz033-B93","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00296-018-4053-x","article-title":"Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity","volume":"38","author":"Biskup","year":"2018","journal-title":"Rheumatol Int"},{"key":"2026091105164246800_pvz033-B94","doi-asserted-by":"crossref","first-page":"R40","DOI":"10.1186\/ar4469","article-title":"Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year","volume":"16","author":"Kay","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2026091105164246800_pvz033-B95","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s10067-018-4038-x","article-title":"Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study","volume":"37","author":"Perrotta","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2026091105164246800_pvz033-B96","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/annrheumdis-2016-209744","article-title":"The role of non-invasive cardiovascular imaging in the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to be","volume":"76","author":"Fent","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B97","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.semarthrit.2008.01.012","article-title":"Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis","volume":"38","author":"Gonzalez-Juanatey","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"2026091105164246800_pvz033-B98","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3899\/jrheum.111334","article-title":"Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis\u2013an inception cohort study","volume":"39","author":"Ajeganova","year":"2012","journal-title":"J Rheumatol"},{"key":"2026091105164246800_pvz033-B99","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/art.30265","article-title":"Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis","volume":"63","author":"Evans","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2026091105164246800_pvz033-B100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/1756-185X.13377","article-title":"Carotid ultrasound findings in rheumatoid arthritis and control subjects: a case-control study","volume":"22","author":"Wah-Suarez","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2026091105164246800_pvz033-B101","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s10067-018-4181-4","article-title":"The best cardiovascular risk calculator to predict carotid plaques in rheumatoid arthritis patients","volume":"37","author":"Wah-Suarez","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2026091105164246800_pvz033-B102","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3899\/jrheum.150510","article-title":"The Framingham score and the systematic coronary risk evaluation at low cutoff values are useful surrogate markers of high-risk subclinical atherosclerosis in patients with rheumatoid arthritis","volume":"43","author":"Dessein","year":"2016","journal-title":"J Rheumatol"},{"key":"2026091105164246800_pvz033-B103","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.berh.2019.03.013","article-title":"Physical activity, exercise and rheumatoid arthritis: effectiveness, mechanisms and implementation","volume":"32","author":"Metsios","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2026091105164246800_pvz033-B104","doi-asserted-by":"crossref","first-page":"131.","DOI":"10.1186\/s12891-017-1473-9","article-title":"Sedentary behaviour is associated with increased long-term cardiovascular risk in patients with rheumatoid arthritis independently of moderate-to-vigorous physical activity","volume":"18","author":"Fenton","year":"2017","journal-title":"BMC Musculoskelet Disord"},{"key":"2026091105164246800_pvz033-B105","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/annrheumdis-2012-202075","article-title":"Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis","volume":"72","author":"Stavropoulos-Kalinoglou","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B106","doi-asserted-by":"crossref","DOI":"10.1002\/art.40892","article-title":"A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis","author":"Kitas","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026091105164246800_pvz033-B107","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3899\/jrheum.160110","article-title":"Cardiovascular outcomes associated with lowering low-density lipoprotein cholesterol in rheumatoid arthritis and matched nonrheumatoid arthritis","volume":"43","author":"An","year":"2016","journal-title":"J Rheumatol"},{"key":"2026091105164246800_pvz033-B108","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3899\/jrheum.110318","article-title":"Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis","volume":"39","author":"Sheng","year":"2012","journal-title":"J Rheumatol"},{"key":"2026091105164246800_pvz033-B109","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/art.34524","article-title":"Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease","volume":"64","author":"Semb","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2026091105164246800_pvz033-B110","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/keq295","article-title":"Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial","volume":"50","author":"Semb","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2026091105164246800_pvz033-B111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2017.11.009","article-title":"Effect of statin therapy on the prevention of new-onset acute coronary syndrome in patients with rheumatoid arthritis","volume":"253","author":"Huang","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026091105164246800_pvz033-B112","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/annrheumdis-2015-207714","article-title":"Statin use and mortality in rheumatoid arthritis: a general population-based cohort study","volume":"75","author":"Schoenfeld","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B113","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/ard.2010.142455","article-title":"Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study","volume":"70","author":"De Vera","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026091105164246800_pvz033-B114","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/acr.21643","article-title":"Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study","volume":"64","author":"De Vera","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2026091105164246800_pvz033-B115","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/art.39114","article-title":"Rosuvastatin-induced carotid plaque regression in patients with inflammatory joint diseases: the Rosuvastatin in rheumatoid arthritis, ankylosing spondylitis and other inflammatory joint diseases study","volume":"67","author":"Rollefstad","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026091105164246800_pvz033-B116","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jacc.2013.04.066","article-title":"Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography\/computed tomography feasibility study","volume":"62","author":"Tawakol","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026091105164246800_pvz033-B117","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jacc.2007.04.076","article-title":"Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis","volume":"50","author":"Maki-Petaja","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026091105164246800_pvz033-B118","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.phrs.2014.02.009","article-title":"Cardiovascular effects of statins, beyond lipid-lowering properties","volume":"88","author":"Mihos","year":"2014","journal-title":"Pharmacol Res"},{"key":"2026091105164246800_pvz033-B119","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00392-016-1069-7","article-title":"Evidence-based goals in LDL-C reduction","volume":"106","author":"Soran","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"2026091105164246800_pvz033-B120","doi-asserted-by":"crossref","first-page":"R90.","DOI":"10.1186\/ar3814","article-title":"Statins accelerate the onset of collagen type II-induced arthritis in mice","volume":"14","author":"Vandebriel","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2026091105164246800_pvz033-B121","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/1744666X.2018.1440206","article-title":"Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations","volume":"14","author":"Selva-O'Callaghan","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2026091105164246800_pvz033-B122","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jamainternmed.2018.2859","article-title":"Association of statin exposure with histologically confirmed idiopathic inflammatory myositis in an Australian population","volume":"178","author":"Caughey","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2026091105164246800_pvz033-B123","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/clc.22862","article-title":"Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience","volume":"41","author":"Ward","year":"2018","journal-title":"Clin Cardiol"},{"key":"2026091105164246800_pvz033-B124","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","article-title":"Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial","volume":"363","author":"McCarey","year":"2004","journal-title":"Lancet"},{"key":"2026091105164246800_pvz033-B125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/msc.160","article-title":"Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients","volume":"8","author":"Toms","year":"2010","journal-title":"Musculoskelet Care"},{"key":"2026091105164246800_pvz033-B126","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3899\/jrheum.100582","article-title":"Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis","volume":"38","author":"El-Barbary","year":"2011","journal-title":"J Rheumatol"},{"key":"2026091105164246800_pvz033-B127","first-page":"69","article-title":"The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis","volume":"33","author":"Lv","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2026091105164246800_pvz033-B128","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2017.10.013","article-title":"The anti-inflammatory effects of statins on patients with rheumatoid arthritis: a systemic review and meta-analysis of 15 randomized controlled trials","volume":"17","author":"Li","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2026091105164246800_pvz033-B129","article-title":"Finding the balance between benefits and harms when using statins for primary prevention of cardiovascular disease: a modeling study","author":"Yebyo","year":"2018","journal-title":"Ann Intern Med"},{"key":"2026091105164246800_pvz033-B130","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1161\/CIR.0000000000000626","article-title":"Systematic review for the 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","volume":"139","author":"Wilson","year":"2019","journal-title":"Circulation"},{"key":"2026091105164246800_pvz033-B131","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026091105164246800_pvz033-B132","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026091105164246800_pvz033-B133","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11883-004-0104-8","article-title":"The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy","volume":"6","author":"Fazio","year":"2004","journal-title":"Curr Atheroscler Rep"},{"key":"2026091105164246800_pvz033-B134","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1124\/pr.115.012203","article-title":"New era of lipid-lowering drugs","volume":"68","author":"Barter","year":"2016","journal-title":"Pharmacol Rev"},{"key":"2026091105164246800_pvz033-B135","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2174\/138161208783885362","article-title":"Fibrate-associated adverse effects beyond muscle and liver toxicity","volume":"14","author":"Florentin","year":"2008","journal-title":"Curr Pharm Des"},{"key":"2026091105164246800_pvz033-B136","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1759720X12468659","article-title":"Fibrates as therapy for osteoarthritis and rheumatoid arthritis? A systematic review","volume":"5","author":"van Eekeren","year":"2013","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026091105164246800_pvz033-B137","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s00296-012-2613-z","article-title":"The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study","volume":"33","author":"Shirinsky","year":"2013","journal-title":"Rheumatol Int"},{"key":"2026091105164246800_pvz033-B138","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4158\/EP171764.GL","article-title":"American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease-executive summary complete appendix to guidelines","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"2026091105164246800_pvz033-B139","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2026091105164246800_pvz033-B140","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans","volume":"56","author":"Muller","year":"2015","journal-title":"J Lipid Res"},{"key":"2026091105164246800_pvz033-B141","first-page":"415","article-title":"Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNFalpha-inhibitor","volume":"31","author":"Hjeltnes","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2026091105164246800_pvz033-B142","doi-asserted-by":"crossref","first-page":"g4379.","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvz033\/30010056\/pvz033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/6\/2\/104\/70577488\/ehjcvp_6_2_104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/6\/2\/104\/70577488\/ehjcvp_6_2_104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:17:04Z","timestamp":1789118224000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/6\/2\/104\/5545547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,9]]},"references-count":142,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,8,9]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvz033","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2019,8,9]]}}}